Axcella achieves initial milestones with its hematology product candidate AXA4010

This article was originally published here

Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initiated enrollment of subjects with sickle cell

The post Axcella achieves initial milestones with its hematology product candidate AXA4010 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply